{"abstract":"The Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Cancer Institute, both institutes of the National Institutes of Health, Department of Health and Human Services, are contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Cavalry Biosciences, Inc. of San Francisco, CA.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2022/03/11/2022-05140.html","cfr_references":[],"citation":"87 FR 14022","comment_url":null,"comments_close_on":"2022-03-28","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before March 28, 2022 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2022-05140","effective_on":null,"end_page":14023,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2022/03/11/2022-05140.xml","html_url":"https://www.federalregister.gov/documents/2022/03/11/2022-05140/prospective-grant-of-an-exclusive-patent-license-development-and-commercialization-of-fusion","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2022-05140?publication_date=2022-03-11","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2022-03-11/2022-05140/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":200,"last_updated":"2026-09-22 04:15:07 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2022-03-11/pdf/2022-05140.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2022-05140.pdf?1646919920","publication_date":"2022-03-11","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2022/03/11/2022-05140.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T17:24:15Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":14022,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: Development and Commercialization of Fusion Proteins for the Treatment of Growth Disorders and Diseases of Cartilage Degeneration","toc_doc":"Development and Commercialization of Fusion Proteins for the Treatment of Growth Disorders and Diseases of Cartilage Degeneration","toc_subject":"Licenses; Exemptions, Applications, Amendments etc.:\n","topics":[],"type":"Notice","volume":87}